Home Endocrinology & Hormones Estrogen/progestogen Receptor agonist Equol

research use only

Equol Estrogen/progestogen Receptor agonist

Cat.No.S2450

Equol, a metabolite of soybeans, is an important isoflavone in humans, specifically binds to 5α-DHT, and has a modest affinity for recombinant estrogen receptor ERβ. Phase 2.
Equol Estrogen/progestogen Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 242.27

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 242.27 Formula

C15H14O3

 Storage (From the date of receipt)
CAS No. 531-95-3 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles C1C(COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O

Solubility

In vitro
Batch:

DMSO : 48 mg/mL (198.12 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 48 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features
A chiral molecule that can exist as the enantiomers R-equol and S-equol.
Targets/IC50/Ki
ERβ [1]
In vitro
Equol is a metabolite produced from the soy phytoestrogen daidzein by the action of gut microflora. This compound has higher affinity for both ERs (estrogen receptors including ERalpha and ERbeta). It exists as the enantiomers R-equol and S-equol. S-equol has a high binding affinity, preferential for ERbeta with a Ki of 16 nM whereas R-equol binds more weakly and with a preference for ERalpha K with a Ki of 50 nM. [1] This metabolite is superior to all other isoflavones in its antioxidant activity. [2] It has antioestrogenic properties. [3] This compound is a 100-fold more potent than daidzein in stimulating an oestrogenic response. It is also more effective than daidzein in competing with 3 H-oestradiol for binding to the ER. This chemical stimulates the growth of MCF-7 cells in a concentration-dependent manner. Although it exhibits oestrogenic activity, exposure of MCF-7 cells to this compound simultaneously with oestradiol is effective in reducing pS2 mRNA expression. It results in the downregulation of ER mRNA expression. [4]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06133101 Recruiting
Non-Alcoholic Fatty Liver Disease
Marialena Mouzaki|Children''s Hospital Medical Center Cincinnati
 January 15 2024 Phase 2
NCT06398236 Recruiting
Menopause
Nutrition & Sante Iberia|Adknoma Health Research
 March 17 2023 Not Applicable
NCT01982578 Completed
Alzheimer''s Disease
Fundación para la Investigación del Hospital Clínico de Valencia|University of Valencia
 September 1 2017 Not Applicable
NCT03101085 Completed
Alzheimer Disease
Russell Swerdlow|Ausio Pharmaceuticals LLC|University of Kansas Medical Center
 May 5 2017 Phase 1|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map